IPWatchdog.com is in the process of transitioning to a newer version of our website. Please be patient with us while we work out all the kinks.
More than 30 years ago the National Cancer Institute began to explore what was then a heretical idea: a patient’s own immune system could be employed to fight cancer. Today, the resulting field of medicine is called immunotherapy, and common practice in hospitals around the world. It is also a fast-growing field. Numerous companies have begun studies and filed for patent applications. To date, over 5,000 immunotherapy patents have already been published, and the number of patents continues to increase.
A report on the cancer immunotherapy market estimates the size of the global market to be worth $88 billion USD in 2020 and predicts the global market to grow with a compounded annual growth rate (CAGR) of 12.52% over the forecast period from 2020-2025, reaching $158 billion USD by 2025.
Join Gene Quinn, President & CEO of IPWatchdog, Inc., for a wide-ranging conversation about immunotherapy in general, and cancer immunotherapy specifically. We will discuss ongoing research and development, patenting activities and pitfalls, as well as patent enforcement and infringement. Joining Gene will be Dr. Rachel Elsby, Ph.D., a litigation partner at Akin Gump who represents clients in a broad range of sectors, with a particular focus on biotechnology, biologics, and medical devices; and Dr. Carla Mouta-Bellum, Ph.D., a patent attorney and partners with Arrigo, Lee, Guttman & Mouta-Bellum, who specializes in advanced therapies for cancer, infections, and Alzheimer’s Disease.